基于血液转录风险评分预测慢阻肺发病与肺功能下降
研究利用COPDGene队列2,569例全血RNA测序数据,随机分为训练集1,945例和测试集624例,并在ECLIPSE队列468例中复制,开发了包含147个转录本的转录风险评分(TRS)。TRS与慢阻肺(OR 3.3)、FEV1年下降(β -17 ml/yr)相关,在ECLIPSE中复制了FEV1下降关联(β -8.2)。联合多基因风险评分(PRS)、TRS和临床因素预测慢阻肺的AUC达0.84,优于单一评分或临床因素模型。
要点
- 基于147个转录本构建的TRS与慢阻肺风险(OR 3.3)及FEV1年下降(β -17 ml/yr)独立相关。
- TRS联合PRS和临床因素预测慢阻肺的AUC为0.84,优于单一评分或临床因素模型。
- TRS对FEV1下降的关联在ECLIPSE队列中得到复制(β -8.2 ml/yr)。
核心结论
- 血液转录组学评分加入PRS和临床危险因素后,可改善慢阻肺及肺功能下降的预测。
研究设计与样本
- 研究将COPDGene队列2,569例有全血RNA测序的参与者随机分为训练集1,945例和测试集624例,并以ECLIPSE队列468例有微阵列数据的慢阻肺病例进行复制。
- 采用惩罚回归(LASSO)建模FEV1/FVC以开发转录风险评分(TRS),并评估其对慢阻肺(GOLD 2-4)、前瞻性FEV1变化(ml/yr)及其他慢阻肺相关特征的预测价值,调整年龄和吸烟等混杂因素。
主要发现
- TRS包含147个转录本,与慢阻肺相关(OR 3.3;95%CI 2.4-4.5;P<0.001)。
- TRS与FEV1年变化相关(β -17 ml/yr;95%CI -28至-6.6;P=0.002)。
- 在ECLIPSE病例中复制了TRS与FEV1变化的关联(β -8.2;95%CI -15至-1;P=0.025)及多数其他慢阻肺相关特征。
- 包含PRS、TRS和临床因素的模型预测慢阻肺的AUC为0.84,对年化FEV1变化的预测也优于仅含一个风险评分或临床因素的模型。
临床怎么用
- 对于慢阻肺风险评估,可考虑在临床因素和PRS基础上联合血液转录风险评分,以提高对发病和肺功能下降的预测能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: The ability of peripheral blood biomarkers to assess chronic obstructive pulmonary disease (COPD) risk and progression is unknown. Genetics and gene expression may capture important aspects of COPD-related biology that predict disease activity. Objectives: Develop a transcriptional risk score (TRS) for COPD and assess the contribution of the TRS and a polygenic risk score (PRS) for disease susceptibility and progression. Methods: We randomly split 2,569 COPDGene (Genetic Epidemiology of COPD) participants with whole-blood RNA sequencing into training (n = 1,945) and testing (n = 624) samples and used 468 ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points) COPD cases with microarray data for replication. We developed a TRS using penalized regression (least absolute shrinkage and selection operator) to model FEV1/FVC and studied the predictive value of TRS for COPD (Global Initiative for Chronic Obstructive Lung Disease 2-4), prospective FEV1 change (ml/yr), and additional COPD-related traits. We adjusted for potential confounders, including age and smoking. We evaluated the predictive performance of the TRS in the context of a previously derived PRS and clinical factors. Measurements and Main Results: The TRS included 147 transcripts and was associated with COPD (odds ratio, 3.3; 95% confidence interval [CI], 2.4-4.5; P < 0.001), FEV1 change (β, -17 ml/yr; 95% CI, -28 to -6.6; P = 0.002), and other COPD-related traits. In ECLIPSE cases, we replicated the association with FEV1 change (β, -8.2; 95% CI, -15 to -1; P = 0.025) and the majority of other COPD-related traits. Models including PRS, TRS, and clinical factors were more predictive of COPD (area under the receiver operator characteristic curve, 0.84) and annualized FEV1 change compared with models with one risk score or clinical factors alone. Conclusions: Blood transcriptomics can improve prediction of COPD and lung function decline when added to a PRS and clinical risk factors.
引用
- Moll M, Boueiz A, Ghosh AJ, et al. Development of a Blood-based Transcriptional Risk Score for Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2022. PMID: 34739356. doi:10.1164/rccm.202107-1584OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。